Aiforia releases another CE-IVD marked clinical AI Model — expanding its diagnostic pathology offering to prostate cancer
Aiforia Technologies Plc, Press Release, 27 May, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Prostate Cancer; Gleason Grade Groups. This latest regulatory certification brings Aiforia’s portfolio of AI-powered diagnostic tools to a total of 5 CE-IVD marked clinical AI models for breast, lung, and now prostate cancer — the most commonly occurring cancer in men.According to the World Cancer Research Fund, more than 1.4 million new cases of prostate cancer were diagnosed in 2020. Both pathologists and patients deserve